Harnessing the immune system to treat myeloma

About this module

Dr Chris Parrish outlines the rationale for harnessing the immune system as a therapeutic strategy in myeloma and provides examples of the different types of immunotherapy under investigation.

CPD hours: 1


Hari P et al. (2011) Reduced intensity allogeneic hematopoietic stem cell transplant for myeloma – chronic graft versus host disease is associated with lower risk of relapse and superior progression free survival – A CIBMTR analysis. Blood 114: 53.

Lee DW et al. (2012) The future is now: chimeric antigen receptors as new targeted therapies for childhood cancers. Clin Cancer Res. 18: 2780-2790.

Russell SJ et al. (2014) Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89: 926-933.


Al-Hujaily EM et al. (2016) Development of novel immunotherapies for multiple myeloma. Int. J. Mol. Sci. 17: 1506; doi: 10.3390/ijms17091506

Kocoglu M and Badros A. (2016) The role of immunotherapy in multple myeloma. Pharmaceuticals 9:(1). pii E3. doi 10.3390/ph9010003.

Watch the following animation on immunotherapy in myeloma.

Take the CPD quiz

Sorry. You must be logged in to view this form.